The FDA approved three anti-CD19 CAR-T cell products: tisagenleucel (Kymriah), axicabtagen ciloleucel (Yescarta), and brexucabtagene autoleucel (Tecartus) for CD19+ B cell malignancies, such as B-ALL, diffuse large B cell lymphoma, and mantle cell lymphoma [76]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.